×
ADVERTISEMENT

tisotumab vedotin-tftv

FDA Fully Approves Tivdak for Recurrent or Metastatic Cervical Cancer

The FDA granted traditional approval to Tivdak for recurrent or metastatic cervical cancer with disease ...

MAY 3, 2024

Load more